Jiménez Irene, Brisse Hervé J, Fréneaux Paul, Sarnacki Sabine, Michon Jean, Orbach Daniel, Pierron Gaelle, Clément Nathalie, Doz François, Escudier Bernard, Schleiermacher Gudrun
Departments of *Pediatric Oncology, Adolescents and Young Adults †Translational Research ‡Radiology §Pathology ¶Somatic Genetics ††INSERM U830 Research Center, Institut Curie ∥Department of Pediatric Surgery, Necker Enfants-Malades Hospital, Assistance Publique #Department of Pediatrics, University of Paris-Descartes, Sorbonne Paris Cité, Paris **Department of Cancer Medicine, Gustave Roussy, Cancer Campus, Grand Paris, University of Paris-Sud, Villejuif, France.
J Pediatr Hematol Oncol. 2017 Jul;39(5):e279-e284. doi: 10.1097/MPH.0000000000000774.
Antiangiogenic drugs are currently standard of care in adults with renal cell carcinoma (RCC), including translocation RCC. Although antitumor activity and toxicity profile are well known in adults, few data have been reported in children. Here we present the case of a patient diagnosed at 2 years old with a metastatic translocation RCC, consecutively treated with 5 tyrosine kinase inhibitors during 6 years. The antitumor activity and toxic effects are described, and a brief review of the literature is presented.
抗血管生成药物目前是成人肾细胞癌（RCC）包括易位性RCC的标准治疗方法。尽管其抗肿瘤活性和毒性特征在成人中已广为人知，但在儿童中的报道却很少。在此，我们报告一例2岁时被诊断为转移性易位性RCC的患者，在6年中连续接受了5种酪氨酸激酶抑制剂治疗。描述了其抗肿瘤活性和毒性作用，并对文献进行了简要综述。
